132
Participants
Start Date
February 12, 2018
Primary Completion Date
September 28, 2021
Study Completion Date
September 28, 2021
topiramate
Oral topiramate at a target dose of 50mg twice daily.
Placebo
overencapsulated placebo of identical color, shape and packaging to topiramate
Columbia University Medical Center, New York
University of Rochester Medical Center, Rochester
University of Pennsylvania, Philadelphia
Virginia Commonwealth University, Richmond
Eastern Virginia Medical Center, Norfolk
Wake Forest University Baptist Medical Center, Winston-Salem
University of Miami, Miami
University of Alabama Birmingham, Birmingham
Vanderbilt University Medical Center, Nashville
Ohio State University, Columbus
University of Iowa, Iowa City
Northwestern University, Chicago
Washington University School of Medicine, St Louis
University of Kansas Medical Center, Kansas City
UT Southwestern Medical Center, Dallas
University of Utah, Salt Lake City
Barrow Neurological Institute, Phoenix
University of California Irvine, Orange
Massachusetts General Hospital, Boston
University of Michigan Neurology Clinical Trials Organization, Ann Arbor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
NeuroNEXT Network
OTHER
Virginia Commonwealth University
OTHER